

12 AUG 2002
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Polypeptides Which Posses an Activity of the B-Secretase Type

Examiner: Unassigned

Art Unit: Unassigned

Application No.: 09/701, 945

Filed: December 5, 2000

Title: **POLYPEPTIDES WHICH POSSESS AN
ACTIVITY OF THE B-SECRETASE
TYPE**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

08/10/02
Date of Deposit

Signature
Arreda Parrell

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
Washington, D.C. 20231


Sir:

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Supplemental Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Supplemental Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☐ (b) This Supplemental Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



William C. Coppola, Reg. No. 41,686

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626
Aventis Docket No. USST98014A

☒

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	9/701,945
				Filing Date	12-05-2000
				First Named Inventor	RHOLAM
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	USST98014
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	9/701,945
				Filing Date	12-05-2000
				First Named Inventor	RHOLAM
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	USST98014

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AT	ITOH Takeshi et al., Unaltered Secretion of B-Amyloid Precursor Protein in Gelatinase A (Matrix Metalloproteinase 2)-deficient Mice, The Journal of Biological Chemistry, Vol. 272, No. 36, September 5, 1997, pp. 223,389-22,392	
	AU	LEPAGE Rex N et al., Gelatinase A Possesses a B-secretase-like Activity in Cleaving the Amyloid Protein Precursor of Alzheimer's Disease, FEBS Letters 377, 1995, pp. 267-270	
	AV	MATSUMOTO Akira et al., A Serine Protease in Alzheimer's Disease Cells Cleaves a 16K-peptide with Flanking Residues Upstream to B-amyloid-N-terminus as Natural Substrate, Neuroscience Letters 195 (1995), pp. 171-174	
	AW	MATSUMOTO, Akira et al., Ca ²⁺ -Dependent 68-Kilodalton Protease in Familial Alzheimer's Disease Cells Cleaves the N-Terminus of B-Amyloid, 1993, vol. 33, 3941-3948	
	AX	NELSON Robert B. et al., Clipsin, a Chymotrypsin-like Protease in Rat Brain Which Is Irreversibly Inhibited by alpha-1-Antichymotrypsin, J of Biological Chemistry 265(7):3836-3843 (1990)	
	AY	PAPASTOITSIS, Gregorics et al., Identification of a Metalloprotease from Alzheimers Disease Brain Able to Degrade the B-Amyloid Precursor Protein and Generate Amyloidogenic, 1994, 192-199, vol.	
	AZ	RAZZABONI, Browyn et al., A Calcium-Stimulated Serine Protease from Monkey Brain Degrades the B-Amyloid Precursor Protein, 1992, 207-216, vol. 589	
	BA	SAHASRABUDHE, Sudhir R. et al., Enzymatic Generation of the Amino Terminus of the B-Amyloid Peptide, 01/29/1993, 16699-16705, vol. 268, no. 22	
	BB	SCHONLEIN, Christoph et al., Purification and Characterization of a Novel Metalloprotease From Human Brain with the Ability to Cleave Substates Derived from the N-Terminus of B-Amyloid Protein, May, 30, 1994, vol. 201, No. 1, 45-53	
	BC	THOMPSON, Annick et al., Cloning and Functional Expression of a Metalloendopeptidase from Human Brain with the Ability to Cleave A B-APP Substrate Peptide, 1996, 66-73, vol. 213, no. 1	
	I		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.